Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00191022 · ClinicalTrials.gov registry record · Phase 2

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

A Phase 2 study of Social Phobia, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
185
Enrollment target
15
Study locations

NCT00191022: Completed Phase 2 study of Social Phobia, sponsored by Eli Lilly and Company.

NCT00191022 is a Phase 2 study of Social Phobia that has completed, run by Eli Lilly and Company. The registered enrollment target is 185 participants, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (45% higher). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00191022, a Phase 2 study of Social Phobia, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
185 participants
Enrollment target
15
Study locations

Study Summary

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

Conditions Studied

Social Phobia

Interventions

  • DRUG placebo
  • DRUG paroxetine
  • DRUG LY686017

Study Locations (15)

California

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Burbank
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Newport Beach

Virginia

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Herndon
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Richmond

Colorado

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Denver

Connecticut

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - New Britain

Florida

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Gainesville

Indiana

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Indianapolis

Maryland

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Baltimore

Massachusetts

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Belmont

Trial Details

FieldValue
Enrollment Target 185 participants
Start Date 2004-12
Est. Completion 2007-01
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT00191022 record still lists

NCT00191022 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 128-participant average among 8 other Social Phobia trials with a reported enrollment target (45% higher).

The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00191022 lists 15 locations in 13 states (California, Virginia, Colorado).

Frequently Asked Questions

What is clinical trial NCT00191022 about?

NCT00191022 is a clinical study titled "Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder". This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

What is the current status of trial NCT00191022?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2004-12. Estimated completion is 2007-01.

What conditions does trial NCT00191022 study?

This clinical trial studies the following conditions: Social Phobia.

What interventions are being tested in trial NCT00191022?

The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), LY686017 (DRUG).

Who is sponsoring clinical trial NCT00191022?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00191022 being conducted?

This trial has 15 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Social Phobia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00191022's enrollment target sits among peer trials

185 3rd of 8 higher than 6 of 8 other Social Phobia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Social Phobia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04041154 · 185 participants · NA

    Behavioral and Neural Representations of Subjective Effort Cost

  • NCT04484272 · 185 participants · NA

    A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

  • NCT05020860 · 185 participants · Phase 2

    Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

  • NCT05793541 · 185 participants · NA

    Just-in-time Interventions for Reducing Short-term Suicide Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00191022, the US trial registry maintained by the National Library of Medicine. NCT00191022 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.